615 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Purchased by Norden Group LLC

Norden Group LLC bought a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 615 shares of the pharmaceutical company’s stock, valued at approximately $250,000.

Several other institutional investors also recently added to or reduced their stakes in VRTX. Vanguard Group Inc. grew its holdings in shares of Vertex Pharmaceuticals by 0.4% during the 3rd quarter. Vanguard Group Inc. now owns 21,983,356 shares of the pharmaceutical company’s stock worth $7,644,492,000 after purchasing an additional 87,397 shares in the last quarter. Jennison Associates LLC boosted its stake in Vertex Pharmaceuticals by 3.9% during the fourth quarter. Jennison Associates LLC now owns 3,944,913 shares of the pharmaceutical company’s stock worth $1,605,146,000 after buying an additional 147,248 shares in the last quarter. Morgan Stanley increased its holdings in Vertex Pharmaceuticals by 3.2% in the 3rd quarter. Morgan Stanley now owns 2,870,101 shares of the pharmaceutical company’s stock valued at $998,050,000 after buying an additional 89,217 shares during the period. Northern Trust Corp raised its stake in shares of Vertex Pharmaceuticals by 4.9% in the 3rd quarter. Northern Trust Corp now owns 2,813,563 shares of the pharmaceutical company’s stock valued at $978,388,000 after buying an additional 131,539 shares in the last quarter. Finally, Invesco Ltd. lifted its holdings in shares of Vertex Pharmaceuticals by 3.5% during the 3rd quarter. Invesco Ltd. now owns 2,016,780 shares of the pharmaceutical company’s stock worth $701,315,000 after acquiring an additional 67,451 shares during the period. 90.96% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently weighed in on VRTX. HC Wainwright upped their target price on shares of Vertex Pharmaceuticals from $457.00 to $462.00 and gave the company a “buy” rating in a research note on Thursday, April 11th. Truist Financial increased their price objective on Vertex Pharmaceuticals from $456.00 to $508.00 and gave the stock a “buy” rating in a research note on Wednesday, January 31st. Oppenheimer restated an “outperform” rating and issued a $500.00 target price on shares of Vertex Pharmaceuticals in a research note on Monday, April 15th. Barclays increased their target price on shares of Vertex Pharmaceuticals from $446.00 to $472.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Finally, Guggenheim boosted their target price on Vertex Pharmaceuticals from $445.00 to $450.00 and gave the stock a “buy” rating in a report on Thursday, April 18th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $429.45.

Vertex Pharmaceuticals Stock Performance

Shares of Vertex Pharmaceuticals stock opened at $402.14 on Thursday. The stock’s fifty day simple moving average is $410.17 and its 200 day simple moving average is $399.54. The company has a current ratio of 3.99, a quick ratio of 3.78 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $103.94 billion, a PE ratio of 28.95, a PEG ratio of 1.85 and a beta of 0.39. Vertex Pharmaceuticals Incorporated has a 12 month low of $320.01 and a 12 month high of $448.40.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share for the quarter, beating the consensus estimate of $3.85 by $0.35. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. The business had revenue of $2.52 billion for the quarter, compared to analysts’ expectations of $2.50 billion. During the same quarter in the previous year, the business posted $3.33 EPS. On average, research analysts predict that Vertex Pharmaceuticals Incorporated will post 14.95 EPS for the current year.

Insider Activity

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 354 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $425.70, for a total value of $150,697.80. Following the sale, the executive vice president now owns 55,804 shares of the company’s stock, valued at approximately $23,755,762.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, EVP Ourania Tatsis sold 354 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $425.70, for a total transaction of $150,697.80. Following the completion of the transaction, the executive vice president now directly owns 55,804 shares of the company’s stock, valued at approximately $23,755,762.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Kristen Ambrose sold 1,374 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $420.24, for a total transaction of $577,409.76. Following the completion of the sale, the chief accounting officer now owns 9,676 shares in the company, valued at $4,066,242.24. The disclosure for this sale can be found here. Insiders sold 12,381 shares of company stock worth $5,203,249 over the last quarter. 0.20% of the stock is currently owned by company insiders.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.